ADMA Biologics Employees 2024

ADMA Biologics Aktienanalyse

What does ADMA Biologics do?

ADMA Biologics is a leading company in the development and manufacturing of biological therapies for the treatment of serious diseases. The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics' business model is based on the development and manufacturing of specialized biological therapies tailored to the needs of patients with rare diseases and severe infections. It specializes in the development of plasma-based therapies to treat patients with immune deficiency and autoimmune diseases, hemophilia, and severe blood loss due to trauma or surgery. ADMA Biologics' products include intravenously administered immune globulin (IVIG) called BIVIGAM, approved for intravenous infusion in patients with primary immune deficiency or other immune disorders. CyclASol, an eye drop for patients with the eye inflammation Keratoconjunctivitis Sicca, is also a product developed by ADMA Biologics. Additionally, ADMA Biologics is currently expanding its product portfolio through the development of PDIG, a product in phase III clinical trial for the treatment of secondary immune deficiencies. The company has long-standing partnerships with other companies and organizations in the industry to combine its resources and expertise in the development and marketing of innovative therapies. ADMA Biologics also operates its own plasma collection center to ensure the supply of plasma for its therapies. In terms of its divisions, ADMA Biologics currently focuses on the USA, where the company offers its products through a dedicated sales team. Additionally, ADMA Biologics aims to expand its presence worldwide by introducing its products into new regions and markets. The company has achieved important regulatory milestones in Europe and other parts of the world, including the approval of BIVIGAM's sale in Korea and the Industrial Ministry Jubilee Memorial for BIVIGAM's introduction in Japan. ADMA Biologics' history began in 2004 when the company specialized in the development and manufacturing of plasma-based therapies for patients with rare diseases. In 2009, the company received its first FDA approval for ASCENIV, an immune globulin product for the treatment of immune deficiency disorders. In 2011, ADMA Biologics acquired a plasma collection center to expand its resources and capabilities and ensure an independent supply chain for plasma. Since then, the company has gained importance in the industry through the development and introduction of innovative products and therapies. In 2018, ADMA Biologics established a subsidiary in Germany to support the company's expansion into the European continent. In the same year, the company also obtained FDA approval in the United States for BIVIGAM, the first IVIG product manufactured from human plasma in the country. Overall, ADMA Biologics has a strong brand presence in the industry and is successfully expanding its portfolio of plasma-based therapies. The company has established strong partnerships with organizations in the industry to jointly develop and bring innovative solutions to a wide range of diseases. ADMA Biologics has a very positive future outlook and is expected to play a significant role in the field of biological therapies by continuing to develop and bring innovative therapies to the market. ADMA Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining ADMA Biologics's Employee Base

ADMA Biologics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding ADMA Biologics's operational capacity and future potential.

Year-to-Year Comparison

Assessing ADMA Biologics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

ADMA Biologics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in ADMA Biologics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about ADMA Biologics stock

How many employees does ADMA Biologics have this year?

ADMA Biologics has 406 undefined employees this year.

How many employees did ADMA Biologics have compared to the previous year?

Compared to the previous year, ADMA Biologics had 0% more employees.

What impact did the number of employees have on the company ADMA Biologics?

The number of employees has a direct impact on the efficiency and productivity of ADMA Biologics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of ADMA Biologics?

The number of employees can also have an impact on investors of ADMA Biologics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of ADMA Biologics affect the company?

An increase in equity of ADMA Biologics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in ADMA Biologics's equity affect the company?

A reduction in equity of ADMA Biologics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of ADMA Biologics?

Some factors that can influence the equity of ADMA Biologics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of ADMA Biologics so important for investors?

The equity of ADMA Biologics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at ADMA Biologics influence the company?

The number of employees at ADMA Biologics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at ADMA Biologics evolved in recent years?

In recent years, the number of employees at ADMA Biologics has changed by 0.

How many employees does ADMA Biologics currently have?

ADMA Biologics currently has 406 undefined employees.

Why is the number of employees important for investors of ADMA Biologics?

The number of employees is important for investors of ADMA Biologics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can ADMA Biologics take to change the number of employees?

To change the number of employees, ADMA Biologics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does ADMA Biologics pay?

Over the past 12 months, ADMA Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ADMA Biologics is expected to pay a dividend of 0 USD.

What is the dividend yield of ADMA Biologics?

The current dividend yield of ADMA Biologics is .

When does ADMA Biologics pay dividends?

ADMA Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ADMA Biologics?

ADMA Biologics paid dividends every year for the past 0 years.

What is the dividend of ADMA Biologics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ADMA Biologics located?

ADMA Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ADMA Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ADMA Biologics from 7/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/17/2024.

When did ADMA Biologics pay the last dividend?

The last dividend was paid out on 7/17/2024.

What was the dividend of ADMA Biologics in the year 2023?

In the year 2023, ADMA Biologics distributed 0 USD as dividends.

In which currency does ADMA Biologics pay out the dividend?

The dividends of ADMA Biologics are distributed in USD.